Skip to main content
    Your first consultation is complimentary.
    Board-certified physicians
    US-compounded via 503A partners
    HIPAA-compliant
    Discreet 3–5 day shipping
    Lab-monitored every 90 days
    All peptides
    Tirzepatide vial — Nexphoria, prescription onlyPrescription only

    Tirzepatide · Metabolic

    A metabolic reset on two receptors.

    Tirzepatide — A dual GLP-1 / GIP agonist, titrated under physician supervision with metabolic bloodwork gating each dose step.

    Tirzepatide

    metabolic · physician-prescribed

    Dose
    2.5 → 15 mg weekly SC (titrated)
    Format
    physician-directed · with glycine + B12
    Monitoring
    Panel at baseline · retest every 90 days
    From $279/moon the 12-month cadence · panel included

    A licensed physician decides — and can decline. Dispensed only if prescribed.

    Why this peptide, this way

    Prescribed

    A licensed U.S. physician authorizes it against your intake and your panel, and signs for it.

    Full panel, gated

    Baseline bloodwork is required before the first dose, and read by your physician.

    Retested at 90 days

    The same markers are re-drawn and the dose is held, adjusted, or tapered from data.

    What to expect

    Wk 1

    Appetite signaling changes.

    Wk 4

    Physician reviews response.

    Wk 12

    Reassessed against bloodwork.

    What is included, every month

    Physician review & prescription

    Full bloodwork panel

    503A pharmacy compounding

    Cold-chain, unbranded delivery

    Marker dashboard & messaging

    90-day retest & dose review

    Required bloodwork

    Full panel

    Full panel plus insulin / HOMA-IR.

    See the panels →

    The evidence

    3 peer-reviewed studies on Tirzepatide

    SURMOUNT-1: in 2,539 adults with obesity, tirzepatide produced mean weight reductions of 15–21% over 72 weeks, substantially exceeding placebo and establishing dual GIP/GLP-1 agonism as a leading pharmacotherapy for chronic weight management.

    Published findings for the molecule, not predictions for you. Study populations, doses, and durations differ from any individual protocol. Your physician decides what applies.

    A physician on the Nexphoria review network

    Every Tirzepatide prescription is written by a U.S.-licensed physician who has read your bloodwork — and declined when the numbers say no.

    The Nexphoria clinical standard

    Asked plainly, answered plainly

    Is Tirzepatide FDA-approved?

    No. Like most therapeutic peptides, Tirzepatide is not FDA-approved as a standalone drug. Where a licensed physician determines it appropriate, it is prescribed off-label and compounded for you in a state-licensed 503A pharmacy. Compounded medications are not evaluated by the FDA for safety, effectiveness, or quality.

    Do I need a prescription?

    Yes — always. Every Nexphoria protocol begins with a structured intake reviewed by a US-licensed physician. Nothing ships without a valid prescription, and the consultation is complimentary: you pay only if prescribed.

    What bloodwork is required?

    Tirzepatide is gated on the Full panel — drawn at baseline before anything is prescribed, then retested on a fixed schedule so your physician reads the trend rather than one reading in isolation.

    When do people typically notice changes?

    The protocol timeline outlines appetite signaling changes around Wk 1. Individual response varies — which is exactly why the protocol is monitored with scheduled bloodwork rather than assumed.

    Can I cancel?

    Yes. The 1-month cadence cancels anytime. Longer cadences trade flexibility for price — 15% off at 3 months, 30% off at 12 months with the panel included.

    The point of the protocol

    We sell the measured loop — not the vial.

    Before you begin

    Not for everyone.

    Personal/family history of medullary thyroid carcinoma

    MEN 2

    Pregnancy

    Pancreatitis history

    Compounded preparations are not FDA-approved, and the FDA does not review them for safety or effectiveness. Where an active ingredient is FDA-approved in other products, that approval does not extend to a compounded preparation. Prescribed only where a licensed provider determines it appropriate. This page is educational and is not medical advice.

    The complete route

    Tirzepatide anchors The Ignite protocol.

    A GLP-1 / GIP agonist titrated slowly under physician supervision, with metabolic bloodwork gating every dose increase.

    Tirzepatide
    From $279/mo · if prescribedSee the protocol

    Often prescribed on the same axis

    Compounds your physician may consider alongside Tirzepatide — same intake, same panel, one prescription decision.

    The consultation is complimentary. A figure follows only a prescription.

    Start your assessment